Paper23190886
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
Zhou H and 13 others. J Invest Dermatol, 2013. Cited by 47 papers, by iCite.
Cite this record
ConductScience Library. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. Papers, record 23190886. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23190886
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunologic Factors | Major topic |
| Immunotoxins | Major topic |
| Melanoma | Major topic |
| Receptors, Tumor Necrosis Factor | Major topic |
| Skin Neoplasms | Major topic |
| Animals | |
| Cell Death | |
| Cell Line, Tumor | |
| Drug Design | |
| Female | |
| Humans | |
| Mice | |
| Mice, Inbred BALB C | |
| NF-kappa B | |
| Protein Binding | |
| Signal Transduction | |
| TWEAK Receptor | |
| Up-Regulation | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| R01 CA130940 | NCI NIH HHS | United States | R01CA130940 | PubMed and NIH | NIH RePORTER |
| T32 HL007698 | NHLBI NIH HHS | United States | T32HL007698 | PubMed and NIH | NIH RePORTER |
| CA16672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| CA125103 | NCI NIH HHS | United States | R01CA125103 | PubMed and NIH | NIH RePORTER |
| R01 NS055126 | NINDS NIH HHS | United States | R01NS055126 | PubMed and NIH | NIH RePORTER |
| R01 CA125103 | NCI NIH HHS | United States | R01CA125103 | PubMed and NIH | NIH RePORTER |
| P30CA016672 | NIH | NIH RePORTER |
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12651623 | The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. | Am J Pathol | 2003 | https://conductscience.org/library/papers/12651623 | PubMed |
| 2 | 21697654 | Development of an Fn14 agonistic antibody as an anti-tumor agent. | MAbs | 2011 | https://conductscience.org/library/papers/21697654 | PubMed |
| 3 | 21629286 | Ipilimumab. | Nat Rev Drug Discov | 2011 | https://conductscience.org/library/papers/21629286 | PubMed |
| 4 | 20482674 | Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. | J Cutan Pathol | 2010 | https://conductscience.org/library/papers/20482674 | PubMed |
| 5 | 14713109 | SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. | Clin Exp Metastasis | 2003 | https://conductscience.org/library/papers/14713109 | PubMed |
| 6 | 16015365 | Caspase-independent cell death. | Nat Med | 2005 | https://conductscience.org/library/papers/16015365 | PubMed |
| 7 | 19513634 | Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. | Results Probl Cell Differ | 2009 | https://conductscience.org/library/papers/19513634 | PubMed |
| 8 | 22037033 | Vemurafenib. | Nat Rev Drug Discov | 2011 | https://conductscience.org/library/papers/22037033 | PubMed |
| 9 | 19917835 | Final version of 2009 AJCC melanoma staging and classification. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19917835 | PubMed |
| 10 | 11393586 | Microtiter-based assay for evaluating the biological activity of ribosome-inactivating proteins. | Pharmacol Toxicol | 2001 | https://conductscience.org/library/papers/11393586 | PubMed |
| 11 | 12629507 | Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. | Oncogene | 2003 | https://conductscience.org/library/papers/12629507 | PubMed |
| 12 | 15342808 | Management of cutaneous melanoma. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15342808 | PubMed |
| 13 | 17594693 | Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. | Int J Cancer | 2007 | https://conductscience.org/library/papers/17594693 | PubMed |
| 14 | 12496418 | Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. | J Immunol | 2003 | https://conductscience.org/library/papers/12496418 | PubMed |
| 15 | 18927540 | Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. | J Invest Dermatol | 2008 | https://conductscience.org/library/papers/18927540 | PubMed |
| 16 | 21828059 | Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. | Carcinogenesis | 2011 | https://conductscience.org/library/papers/21828059 | PubMed |
| 17 | 17981048 | TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. | Cytokine | 2007 | https://conductscience.org/library/papers/17981048 | PubMed |
| 18 | 19944700 | Stability and DNA-binding ability of the bZIP dimers formed by the ATF-2 and c-Jun transcription factors. | J Mol Biol | 2010 | https://conductscience.org/library/papers/19944700 | PubMed |
| 19 | 20406483 | Melanoma: a model for testing new agents in combination therapies. | J Transl Med | 2010 | https://conductscience.org/library/papers/20406483 | PubMed |
| 20 | 12789290 | Apoptosis and melanoma chemoresistance. | Oncogene | 2003 | https://conductscience.org/library/papers/12789290 | PubMed |
Cited by40
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40585358 | The TWEAK/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia. | iScience | 2025 | https://conductscience.org/library/papers/40585358 | PubMed |
| 40444089 | Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment. | Front Oncol | 2025 | https://conductscience.org/library/papers/40444089 | PubMed |
| 38404743 | Deciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and d-Peptide Ligand Discovery. | ACS Bio Med Chem Au | 2024 | https://conductscience.org/library/papers/38404743 | PubMed |
| 37812740 | Impact of Targeting Moiety Type and Protein Corona Formation on the Uptake of Fn14-Targeted Nanoparticles by Cancer Cells. | ACS Nano | 2023 | https://conductscience.org/library/papers/37812740 | PubMed |
| 36678596 | Momordica cochinchinensis (Gấc) Seed Extracts Induce Apoptosis and Necrosis in Melanoma Cells. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/36678596 | PubMed |
| 36339601 | Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36339601 | PubMed |
| 36069059 | Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity. | EMBO Mol Med | 2022 | https://conductscience.org/library/papers/36069059 | PubMed |
| 36061481 | Methotrexate Mechanism of Action in Plaque Psoriasis: Something New in the Old View. | J Clin Aesthet Dermatol | 2022 | https://conductscience.org/library/papers/36061481 | PubMed |
| 35707713 | Lower Expression of TWEAK is Associated with Poor Survival and Dysregulate TIICs in Lung Adenocarcinoma. | Dis Markers | 2022 | https://conductscience.org/library/papers/35707713 | PubMed |
| 34917619 | Identification of Pan-Cancer Biomarkers Based on the Gene Expression Profiles of Cancer Cell Lines. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34917619 | PubMed |
| 33937046 | A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma. | Front Oncol | 2021 | https://conductscience.org/library/papers/33937046 | PubMed |
| 32958685 | Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32958685 | PubMed |
| 31998833 | Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. | Sci Adv | 2020 | https://conductscience.org/library/papers/31998833 | PubMed |
| 30218067 | Autophagy differentially regulates TNF receptor Fn14 by distinct mammalian Atg8 proteins. | Nat Commun | 2018 | https://conductscience.org/library/papers/30218067 | PubMed |
| 29681850 | Tnfrsf12a-Mediated Atherosclerosis Signaling and Inflammatory Response as a Common Protection Mechanism of Shuxuening Injection Against Both Myocardial and Cerebral Ischemia-Reperfusion Injuries. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/29681850 | PubMed |
| 29076988 | The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations. | Toxins (Basel) | 2017 | https://conductscience.org/library/papers/29076988 | PubMed |
| 29075649 | Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. | J Immunol Res | 2017 | https://conductscience.org/library/papers/29075649 | PubMed |
| 29054986 | Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. | Mol Cancer Ther | 2018 | https://conductscience.org/library/papers/29054986 | PubMed |
| 28138696 | Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro. | Mol Med Rep | 2017 | https://conductscience.org/library/papers/28138696 | PubMed |
| 28103571 | Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. | Oncotarget | 2017 | https://conductscience.org/library/papers/28103571 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23190886
GET https://conductscience.org/api/papers/v1/23190886/references?page=2